نتایج جستجو برای: somatropin
تعداد نتایج: 1761 فیلتر نتایج به سال:
PURPOSE To report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope®, a somatropin biosimilar to Genotropin®, in Italian patients with growth hormone deficiency (GHD) enrolled in the PATRO Adults study. METHODS The PATRO Adults study is an ongoing observational, longitudinal, non-interventional global post-marketing surveillance study, conducted in sever...
OBJECTIVES Paediatric growth hormone deficiency (pGHD) manifests as failure associated with inadequate (GH) production. Daily injections of recombinant human GH (dGH) [somatropin] is the current standard care, which has been shown to be well tolerated and effective, but suboptimal adherence, leading reduced effectiveness. Somatrogon, a once-weekly injectable long-acting GH, demonstrated clinica...
PURPOSE Persistence and adherence with subcutaneous growth hormone (GH; somatropin) therapy in children is widely acknowledged to be suboptimal. This study aimed to investigate how the use of a jet-delivery device, ZomaJet(®), impacts on medication-taking behaviors compared to needle-based devices. MATERIALS AND METHODS A retrospective cohort study of children aged ≤18 years was conducted usi...
INTRODUCTION A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnitrope®), using a Dialogue Teamwork approach. The feasibility of using this approach to implement th...
introduction intra-articular injections of platelet rich plasma (prp) for the treatment of knee osteoarthritis have been shown to reduce pain and improve joint function. the aim of this study is to examine the joint function by adding intra-articular growth hormone to platelet rich plasma. this study was performed on the individuals with knee osteoarthritis and under ultrasound guidance. conclu...
As the first wave of biopharmaceuticals is set to expire, biosimilars or follow-on protein products (FOPPs) have emerged. The regulatory foundation for these products is more advanced and better codified in Europe than in the US. Recent approval of biosimilar Somatropin (growth hormone) in Europe and the US prompted this paper. The scientific viability of biosimilar growth hormone is reviewed. ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید